ADVERTISEMENT
Sponsored
JCP Special Report
Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia
An interview with Jeff P. Sharman, MD
An interview with Jeff P. Sharman, MD
03/31/2023
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug Administration (FDA) approval of the chronic lymphocytic leukemia (CLL) indication for BRUKINSA® in January 2023.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 10
Issue 3
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Journal of Clinical Pathways Newsletter
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement